Viewing Study NCT02207569


Ignite Creation Date: 2025-12-24 @ 10:46 PM
Ignite Modification Date: 2026-02-21 @ 11:26 PM
Study NCT ID: NCT02207569
Status: COMPLETED
Last Update Posted: 2022-11-02
First Post: 2014-07-24
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Medtronic CoreValve Evolut R U.S. Clinical Study
Sponsor: Medtronic Cardiovascular
Organization:

Study Overview

Official Title: Medtronic CoreValve Evolut R United States IDE Clinical Study
Status: COMPLETED
Status Verified Date: 2022-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk for surgical aortic valve replacement.
Detailed Description: This objective will be accomplished by a prospective, single arm, historical controlled, multi-site study involving a minimum of 150 implanted subjects with no more than 250 implanted subjects at up to 25 study sites in the United States. Procedural and 30 day safety and efficacy results from this study will be compared to appropriate historical control data for the Medtronic CoreValve System. Subjects will be followed up to 5 years following implantation.

The enrollment phase of the study is estimated to take approximately 6-9 months. As each implanted subject is to be followed up to 5 years, the estimated study duration is approximately 66-69 months, excluding the time required for preparing the final report.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: